51 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm
were collected over the COVID-19 pandemic period.
At the AAN meeting, Takeda additionally presented post-hoc analysis data from the Phase 2 ELEKTRA
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
presented by the ongoing COVID-19 pandemic. Additional risks that could cause actual results to differ materially from those in the forward-looking
8-K
EX-99.1
ev8t083lklf2oklz9uo6
9 Aug 22
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
8:18am
8-K
EX-99.1
3y9ojuqhf7
10 May 22
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
8:05am
8-K
EX-99.1
8kqdhu7oh7a5226rs
15 Mar 22
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
8:29am
8-K
EX-99.1
tk7ne526j
3 Jan 22
Entry into a Material Definitive Agreement
7:00am
8-K
EX-99.1
96irfh
10 Nov 21
Corporate Highlights and Financial Results
8:38am
8-K
EX-99.1
yswnkvzqckcoj4q4
18 Aug 21
Regulation FD Disclosure
8:05am
8-K
EX-99.1
8yaprds5
16 Aug 21
Ovid Therapeutics Reports Second Quarter 2021 Financial Results
8:06am
8-K
EX-99.1
p255f
23 Jun 21
Regulation FD Disclosure
8:05am
8-K
EX-99.1
s8pz4jlmh1euxo3z
18 May 21
Regulation FD Disclosure
3:11pm